COMPASS Pathways Q2 2023: $148.2M Cash Position, Steady Quarter And 'Strong Progress Across The Business'
Portfolio Pulse from Lara Goldstein
COMPASS Pathways (NASDAQ:CMPS) reported Q2 2023 financial results, with cash and cash equivalents totaling $148.2 million, up from $143.2 million in Dec. 2022. The company's Q2 financing included $26.9 million through an ATM facility and $28.8 million through a term loan agreement with Hercules Capital (NYSE:HTGC). The company reported a net loss of $28.3 million for Q2 and $52.5 million for H1 2023. CEO Kabir Nath highlighted steady progress across the business, including ongoing Phase 3 COMP360 psilocybin trials in Treatment-Resistant Depression (TRD).
August 04, 2023 | 2:24 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Hercules Capital provided a term loan agreement of $28.8 million to COMPASS Pathways in Q2 2023.
The loan agreement with COMPASS Pathways could be seen as a positive sign of Hercules Capital's business activity and could potentially impact the stock positively in the short term.
CONFIDENCE 90
IMPORTANCE 50
RELEVANCE 50
NEUTRAL IMPACT
COMPASS Pathways reported a net loss of $28.3 million for Q2 2023, but highlighted progress in ongoing Phase 3 COMP360 psilocybin trials.
Despite the reported net loss, the company's ongoing trials and increased cash position may offset negative sentiment. However, the financial loss could still impact the stock negatively in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100